We have recently demonstrated the safety and tolerability of a novel therapeutic regimen employing autologous blood cells chemically coupled with seven myelin peptides to induce antigenspecific tolerance in MS (ETIMS study). The aim of the current study was an extended safety analysis to assess the effect of the ETIMS approach on antibodies to common autoantigens, the myelin peptides used and common recall antigens. None of the patients showed induction of autoantibody responses. One patient had a measurable myelin peptide-specific response at baseline, which was reduced after treatment. Total immunoglobulins and recall antibody responses showed no significant change.
Introduction
Multiple sclerosis (MS) is the most common disabling neurological disease in young adults. It is widely accepted that damage in the central nervous system (CNS) results from a CD4 + -mediated autoimmune attack against myelin sheath associated antigens. 1 We previously established an antigen-specific tolerance protocol that selectively targets these autoreactive T-cells, employing autologous peripheral blood mononuclear cells (PBMC) pulsed with seven myelin peptides of myelin oligodendrocyte glycoprotein (MOG1-20, MOG35-55), myelin basic protein (MBP13-32, MBP83-99, MBP111-129, MBP146-170) and proteolipid protein (PLP139-154) and chemically fixed with the crosslinker EDC. We demonstrated the feasibility, safety and tolerability of a single infusion of chemically peptide-coupled PBMCs as a tolerogenic vaccine in an open-label, singlecenter, dose-escalation phase 1 trial (ETIMS trial). 2 Furthermore, patients receiving more than 1 × 10 9 peptide-coupled cells showed a decrease in antigenspecific T cell responses.
The aim of this study was to expand our safety analysis on ETIMS-treated patients, analyzing the effect of antigen-coupled cells on the antibody responses against the target myelin peptides, common autoantigens, and recall antigens.
Patients and methods

Patients and serum samples
The ETIMS trial was performed with the approval of the ethics board of physicians of the University Hospital Hamburg-Eppendorf. 2 In the dose-escalation study, patients received a single infusion of autologous antigen-coupled cells at day 0 (individual doses shown in Table 1 ). Serum samples were taken from MS patients one month before, three (patients #1-#7 and #9) or six (patient #8) months and 12 months (all patients) after treatment. All serum samples were stored at −80°C. Furthermore, all patients had a measurable T cell response to at least one of the peptides used in the trial, at baseline. 2 
Antibody assays
All serum samples were analyzed for immunoglobulin (Ig)G antibodies to native human MOG by a live cell-based immunoassay (CBA) as described previously. 3 For the determination of rheumatoid factors (RF) and IgG antibodies against tetanus toxin, rubella, measles, anti-citrullinated peptide (CCP) and phospholipids commercially available ELISA kits from IBL International (Hamburg, Germany) were used. IgG antibodies to Epstein-Barr virus nuclear antigen (EBNA-1) and cytomegalovirus (CMV) were analyzed using ELISA kits from Euroimmun (Luebeck, Germany). Antinuclear antibodies (ANA) were analyzed by indirect immunofluorescence (IIF) in HEp-20-10 cells using an IIF kit from Euroimmun.
Serum samples were analyzed for total IgG, IgM and IgA levels using a Beckman clinical nephelometer (Beckman Coulter).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 6 (GraphPad, USA).
Results
In this study we aimed to investigate antibody responses against myelin peptides, native human MOG, common autoantigens and recall antigens in patients treated with the ETIMS approach ( Figure 1 and Table 2 ). None of the patients had antibodies against native MOG, CCP, phospholipids and RF, whereas two patients had ANA (patients #2 and #7) and two patients had anti-MBP antibodies (patients #5 and #7). In patient #5 anti-MBP antibody levels were reduced (>2-fold change) three and 12 months after treatment (Figure 1 ). Importantly, no new autoantibody responses were induced by the treatment ( Figure 1 and Table 2 ).
Only one patient (patient #2) had measurable antibody reactivities against eight of nine myelin peptides used in the trial. These antibody responses were reduced (>2-fold change) three and 12 months after treatment (Figure 1 ). However, this reduction was also seen for RF levels (>2-fold change).
Finally antibody responses to common recall antigens and total serum albumin and Ig levels were tested to address a peptide-specific effect of this therapy and to potentially exclude unspecific responses to the treatment. Overall antibody responses and Ig levels were not altered (>2-fold change) by the treatment ( Figure 1, Table 2 ).
Discussion
In this extension study we analyzed the influence of the ETIMS approach on the antibody reactivity to common autoantigens, the myelin peptides used and common recall antigens. An important safety issue of antigen-specific tolerization is the induction of immune responses against the tolerizing antigen or even new autoantigens. Therefore, we were interested in assessing changes in antibody responses to myelin peptides used for tolerization, native human MOG and MBP, other targets of autoimmunity responses and recall and control antibodies in any of the treated patients. As one important result of the safety analysis, we did not observe an increase in antimyelin antibody reactivity, supporting the safety of the approach with regard to a potential induction of autoimmune responses as observed in previous tolerization strategies. 6 Next we were interested in excluding potential induction of new autoimmunity by the treatment. Since antigen-coupled cells are known to undergo apoptosis after treatment, 2, 7 there is a concern about induction of ANA. In several autoimmune diseases, including lupus, mixed connective tissue disease and others, antibodies against nuclear antigens (e.g. ANA) are thought to be stimulated and sustained by apoptotic cells. In the current study we could not observe induction of ANA in any of the patients. Likewise, we did not detect an induction of anti-CCP, antiphospholipid antibodies or RF in any of the patients.
We found a positive antibody response to eight of nine myelin peptides in one single patient (#2) at baseline. Since this patient was negative for antibodies to native MOG, it is very unlikely that these peptide-specific antibodies have a pathogenic role, although they still might reflect tissue damage and ongoing neuroinflammation. 3, [8] [9] [10] There was a clear reduction in myelin peptide-specific antibody responses following ETIMS treatment. However, we have also observed a reduction of RF and anti-rubella antibodies thus challenging the specificity of the effect.
In summary the extended safety analysis of the ETIMS phase 1 study does not suggest an increase in autoantibodies or induction of new autoantibody reactivities in MS patients treated with the ETIMS approach. The results underscore the safety of this novel antigen-specific therapy.
